MedDataX Logo

Middle Meningeal Artery Embolization for Chronic Migraine

NCT ID: NCT07044648

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this study is to find out how well middle meningeal artery coil embolization works for patients with recurrent chronic migraines that are not resolved with medication.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study seeks to evaluate the therapeutic potential of middle meningeal artery coil embolization as an interventional strategy for patients with recurrent and pharmacoresistant chronic migraine. Middle meningeal artery embolization has recently gained recognition as a safe and effective intervention for the management of chronic subdural hematoma, demonstrating a low complication profile. The procedure achieves therapeutic effect by reducing or occluding arterial flow within the middle meningeal artery, thereby minimizing arterial dilatation and facilitating hematoma resorption over time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

chronic migraine drug-resistant migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Middle Meningeal Artery Embolization

Participants receive middle meningeal artery embolization

Group Type EXPERIMENTAL

Middle Meningeal Artery Embolization

Intervention Type PROCEDURE

Middle meningeal artery embolization using particles or coils

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Middle Meningeal Artery Embolization

Middle meningeal artery embolization using particles or coils

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with diagnosis of migraine with or without aura, chronic migraine, unilateral or bilateral, moderate to severe intensity, 4-72 hours, familiar or sporadic, status migrainosus, primary or secondary
* Patient who failed pharmacologic treatment (at least 2 failed drugs treatment for more than 3 months) or have considerable side effects
* Patient with diagnosis of migraine and preference for embolization treatment
* Clinical follow up of at least 3 months

Exclusion Criteria

* Presence of patent middle meningeal artery homolateral to the side of migraine


* Previous middle meningeal artery embolization for subdural hematoma
* Previous craniotomy
* Patients aged 17 years or younger.
* Incomplete embolization of middle meningeal artery
* Patient with baseline CTH or MR brain showing baseline intracranial pathology that can explain migraine
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wake Forest University Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hamad Farhat, MD

Role: PRINCIPAL_INVESTIGATOR

advocate christ medical center

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hamad Farhat, MD

Role: CONTACT

Phone: 786.208.5911

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB00131621

Identifier Type: -

Identifier Source: org_study_id